Ionis Pharmaceuticals logo

Ionis PharmaceuticalsNASDAQ: IONS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 May 1991

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$5.33 B
-30%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector
-71%vs. 3y high
90%vs. sector
-45%vs. 3y high
68%vs. sector

Price

after hours | Tue, 19 Nov 2024 21:20:00 GMT
$33.75-$0.41(-1.20%)

Dividend

No data over the past 3 years
$133.81 M$144.98 M
$133.81 M-$140.48 M

Analysts recommendations

Institutional Ownership

IONS Latest News

Ionis to present at upcoming investor conferences
prnewswire.com07 November 2024 Sentiment: POSITIVE

CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Guggenheim's Inaugural Healthcare Conference on Wednesday, November 13, 2024 UBS Global Healthcare Conference on Wednesday, November 13, 2024 Stifel 2024 Healthcare Conference on Monday, November 18, 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024 Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events.

Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
seekingalpha.com06 November 2024 Sentiment: POSITIVE

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia – Chief Executive Officer Eugene Schneider – Chief Clinical Development Officer Kyle Jenne – Chief Global Product Strategy Officer Beth Hougen – Chief Financial Officer Jonathan Birchall – Chief Commercial Officer Eric Swayze – Executive Vice President of Research Richard Geary – Chief Development Officer Conference Call Participants Gary Nachman – Raymond James Jessica Fye – JPMorgan Avi Novick – Morgan Stanley Yanan Zhu – Wells Fargo Securities Luca Issi – RBC David Lebowitz – Citi Jason Gerberry – Bank of America Jay Olson – Oppenheimer Mani Foroohar – Leerink Andy Chen – Wolfe Research Operator Good morning and welcome to the Ionis Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
zacks.com06 November 2024 Sentiment: POSITIVE

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com06 November 2024 Sentiment: POSITIVE

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago.

Ionis reports third quarter 2024 financial results
prnewswire.com06 November 2024 Sentiment: POSITIVE

WAINUA TM  U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif. , Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024.

Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
zacks.com04 November 2024 Sentiment: POSITIVE

Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Ionis to hold third quarter 2024 financial results webcast
prnewswire.com23 October 2024 Sentiment: NEUTRAL

Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

AstraZenca drug for nerve damage given EU Green light
proactiveinvestors.co.uk21 October 2024 Sentiment: POSITIVE

AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis, a rare disease that damages nerves and leads to disability. The green light is based on a successful phase III trial, showing the drug improved patients' nerve function and quality of life compared to a placebo.

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
prnewswire.com21 October 2024 Sentiment: POSITIVE

- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo CARLSBAD, Calif. , Oct. 21, 2024  /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN.

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
prnewswire.com03 October 2024 Sentiment: POSITIVE

–   Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE).

What type of business is Ionis Pharmaceuticals?

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, specializing in research and development of RNA-targeted therapy. It was founded in 1989. The product portfolio includes more than 40 potential drugs aimed at treating a wide range of therapeutic diseases. Currently, the company has three commercially approved drugs in major markets worldwide: SPINRAZA, TEGSEDI, and WAYLIVRA. There are also four drugs undergoing the company's main research: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-L Rx for cardiovascular diseases, and AKCEA-TTR-L Rx for ATTR amyloidosis treatment.

What sector is Ionis Pharmaceuticals in?

Ionis Pharmaceuticals is in the Healthcare sector

What industry is Ionis Pharmaceuticals in?

Ionis Pharmaceuticals is in the Biotechnology industry

What country is Ionis Pharmaceuticals from?

Ionis Pharmaceuticals is headquartered in United States

When did Ionis Pharmaceuticals go public?

Ionis Pharmaceuticals initial public offering (IPO) was on 17 May 1991

What is Ionis Pharmaceuticals website?

https://www.ionispharma.com

Is Ionis Pharmaceuticals in the S&P 500?

No, Ionis Pharmaceuticals is not included in the S&P 500 index

Is Ionis Pharmaceuticals in the NASDAQ 100?

No, Ionis Pharmaceuticals is not included in the NASDAQ 100 index

Is Ionis Pharmaceuticals in the Dow Jones?

No, Ionis Pharmaceuticals is not included in the Dow Jones index

When was Ionis Pharmaceuticals the previous earnings report?

No data

When does Ionis Pharmaceuticals earnings report?

The next expected earnings date for Ionis Pharmaceuticals is 21 February 2025